Form 4: Oric Pharmaceuticals Chief Medical Officer Reports Stock Transactions

Oric Pharmaceuticals' Chief Medical Officer, Pratik S. Multani, executed stock transactions involving the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Summary

• Pratik S. Multani, Chief Medical Officer of Oric Pharmaceuticals, reported transactions involving the company's common stock.
• On December 15, 2024, Multani acquired 24,042 shares through the vesting of restricted stock units (RSUs) at a price of $0.
• These RSUs were part of awards that vest over multiple years.
• Specifically, 6,042 RSUs vested from an award that vests annually on December 15th from 2022 to 2024.
• 8,000 RSUs vested from an award that vests annually on December 15th from 2023 to 2025.
• 10,000 RSUs vested from an award that vests annually on December 15th from 2024 to 2026.
• On December 16, 2024, Multani sold 8,850 shares at a weighted average price of $8.2817 per share, with prices ranging from $8.27 to $8.41.
• The sale was to cover tax withholding obligations related to the vesting of the RSUs and was not a discretionary sale.
• Following these transactions, Multani beneficially owns 46,765 shares of Oric Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing detailing stock transactions by a company insider. It does not indicate any positive or negative sentiment, it is a neutral reporting of events.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders reporting transactions in their company's stock. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The vesting schedules for the RSUs are typical for employee equity compensation plans.
• The sale of shares to cover tax obligations is a common practice among employees who receive equity compensation.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve a small number of shares relative to the total outstanding shares.
• The transactions are part of the company's compensation plan for its employees.

Key Dates

Keywords

insider trading, stock transactions, restricted stock units, vesting, Form 4, Oric Pharmaceuticals, ORIC, Pratik S. Multani, Chief Medical Officer